SML3182

Eltrombopag

≥98% (HPLC)

• 别名: (Z)-3′-(2-(1-(3,4-Dimethylphenyl)-3-methyl-5-oxo-1H-pyrazol-4(5H)-ylidene)hydrazinyl)-2′-hydroxybiphenyl-3-carboxylic acid, 3′-[(2Z)-2-[1-(3,4-Dimethylphenyl)-1,5-dihydro-3-methyl-5-oxo-4H-pyrazol-4-ylidene]hydrazinyl]-2′-hydroxy[1,1′-biphenyl]-3-carboxylic acid, SB 497115, SB-497115, SB497115
• 经验公式（希尔记法）: C₂₅H₂₂N₄O₄
• CAS号: 496775-61-2
• 分子量: 442.47
• MDL號碼: MFCD20926253
• 分類程式碼代碼: 12352200
• NACRES: NA.77

属性

• 品質等級: 100
• 化驗: ≥98% (HPLC)
• 形狀: powder
• 顏色: faint yellow to dark orange
• 溶解度: DMSO: 2 mg/mL, clear
• 儲存溫度: 2-8°C
• SMILES 字串: OC1=C(C=CC=C1N/N=C2C(C)=NN(C/2=O)C3=CC(C)=C(C=C3)C)C4=CC=CC(C(O)=O)=C4

说明

生化／生理作用

Eltrombopag is an orally active nonpeptide thrombopoietin receptor (TpoR) agonist that selectively induces STAT activation and proliferation (EC50 = 270 & 30 nM, respectively) of hToR-transfected, but not non-transfected, BAF3 cells. Eltrombopag increases the differentiation of primary human CD34(+) bone marrow cells into CD41(+) megakaryocytes ex vivo (EC50 = 100 nM) and exhibits thrombopoietic activity in chimpanzees in vivo (10 mg/kg/day p.o.).

安全信息

• 象形圖: GHS08,GHS05,GHS07,GHS09
• 訊號詞: Danger
• 危險聲明: H302,H318,H373,H411
• 防範說明: P260 - P273 - P280 - P301 + P312 - P305 + P351 + P338 - P314
• 危險分類: Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - STOT RE 2
• 儲存類別代碼: 11 - Combustible Solids
• 水污染物質分類（WGK）: WGK 3
• 閃點（°F）: Not applicable
• 閃點（°C）: Not applicable